| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
Vanilpyruvic acid targets adrenergic receptors, monoamine transporters, and opioid receptors. As a catecholamine metabolite, it is involved in the regulation of physiological processes as well as neurological, psychiatric, endocrine, and cardiovascular diseases. It functions as an endogenous metabolite and drug metabolite.
|
|---|---|
| ln Vitro |
Catecholamines, dopamine, norepinephrine, and epinephrine are chemical neurotransmitters and hormones that regulate physiological processes as well as the onset and progression of neurological, psychiatric, endocrine, and cardiovascular illnesses [1]. The catecholamines, which include dopamine (3,4-dihydrophenylethylamine), norepinephrine (norepinephrine), and epinephrine (epinephrine), function as neurotransmitters or hormones both centrally and peripherally. Dopamine, the most prevalent monoamine neurotransmitter, is also found in non-neuronal tissues such as the gastrointestinal system and kidneys, where it regulates sodium balance [2].
In vitro, Vanilpyruvic acid exhibits potential neuroprotective effects, antioxidant properties, and implications in metabolic disorders. As a metabolic intermediate, it participates in oxidative deamination of phenolic compounds and energy metabolism pathways. The compound's catecholamine metabolite status suggests roles in neurotransmitter metabolism and signaling. |
| ln Vivo |
In vivo, Vanilpyruvic acid functions as a metabolic intermediate in the catecholamine degradation pathway. As a metabolite of dopamine, norepinephrine, and epinephrine, it contributes to the regulation of physiological processes and disease progression. However, direct pharmacological effects of the compound itself are not extensively characterized.
|
| Enzyme Assay |
In vitro enzyme assays for Vanilpyruvic acid typically involve studying its role as a substrate or product in metabolic pathways. The compound is used in assays measuring catecholamine metabolism and oxidative deamination. Enzyme activities such as monoamine oxidase or catechol-O-methyltransferase can be assessed using Vanilpyruvic acid as a reference standard or metabolic marker.
|
| Cell Assay |
Cellular assays for Vanilpyruvic acid are conducted using neuronal or metabolic cell lines. Cells are treated with the compound at various concentrations (1-100 uM) to assess its effects on oxidative stress markers, mitochondrial function, or neurotransmitter metabolism. Antioxidant activity is evaluated using DPPH or ABTS radical scavenging assays. Neuroprotective effects are assessed in models of oxidative stress-induced cell death.
|
| Animal Protocol |
In vivo animal studies for Vanilpyruvic acid are typically focused on its role as a metabolite rather than a pharmacologically active compound. It is measured as a biomarker in urine or plasma samples from animal models of metabolic or neurological disorders. The compound is not typically administered as a therapeutic agent but serves as an indicator of catecholamine metabolism.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for Vanilpyruvic acid are limited, as it is an endogenous metabolite rather than a therapeutic drug. It is produced and metabolized as part of normal catecholamine catabolism. The compound is typically measured in biological fluids using HPLC or LC-MS/MS methods. No specific PK parameters have been characterized.
|
| Toxicity/Toxicokinetics |
Toxicological data for Vanilpyruvic acid are not extensively characterized. As an endogenous metabolite, it is naturally present in the body at physiological concentrations. No significant toxicity has been reported for the compound at concentrations relevant to normal metabolism. Standard laboratory safety precautions apply when handling the compound.
|
| References |
|
| Additional Infomation |
Vanilpyruvic is a 2-oxomonocarboxylic acid, a derivative of 3,4-dihydroxyphenylpyruvate, in which the hydroxyl group at the 3-position is replaced by a methoxy group. It is a metabolic product found in human urine. It is a 2-oxomonocarboxylic acid, a monomethoxybenzene, belonging to the phenolic class of compounds. Its function is related to that of 3,4-dihydroxyphenylpyruvate. It is the conjugate acid of Vanilpyruvic.
Vanilpyruvic acid is a research-use compound not approved for clinical therapeutic applications. It is used as a reference standard and biomarker in studies of catecholamine metabolism, neurodegenerative diseases, and metabolic disorders. The compound is valuable for understanding the role of catecholamine metabolites in health and disease and for developing diagnostic assays for metabolic disorders. |
| Molecular Formula |
C10H10O5
|
|---|---|
| Molecular Weight |
210.1834
|
| Exact Mass |
210.053
|
| CAS # |
1081-71-6
|
| PubChem CID |
14124
|
| Appearance |
White to yellow solid powder
|
| Density |
1.374g/cm3
|
| Boiling Point |
402ºC at 760mmHg
|
| Flash Point |
162.1ºC
|
| Vapour Pressure |
3.49E-07mmHg at 25°C
|
| Index of Refraction |
1.575
|
| LogP |
0.597
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
15
|
| Complexity |
250
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
YGQHQTMRZPHIBB-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C10H10O5/c1-15-9-5-6(2-3-7(9)11)4-8(12)10(13)14/h2-3,5,11H,4H2,1H3,(H,13,14)
|
| Chemical Name |
3-(4-hydroxy-3-methoxyphenyl)-2-oxopropanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ≥ 27 mg/mL (~128.46 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (9.90 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 2.08 mg/mL (9.90 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.7578 mL | 23.7891 mL | 47.5783 mL | |
| 5 mM | 0.9516 mL | 4.7578 mL | 9.5157 mL | |
| 10 mM | 0.4758 mL | 2.3789 mL | 4.7578 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
